We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Drove Ingevity Corporation to a New 52-week High?
Read MoreHide Full Article
Shares of Ingevity Corporation (NGVT - Free Report) reached a new 52-week high of $46.71 on Sep 15, before closing the trading session slightly lower at $46.21. This apex improved upon the last 52-week high of $46.57 on Sep 6.
The trading volume for the session on Sep 15 was 0.56 million shares. Earnings estimate revisions for 2016 and 2017 as well as estimated earnings growth rate of 10% for the next 3−5 years indicate Ingevity Corporation’s potential for further price appreciation.
Growth Drivers
Financial performance of Ingevity Corporation in the last quarter was impressive, with earnings of 66 cents per share surpassing the Zacks Consensus Estimate of 49 cents by 34.7%. The decline of 5.1% in net sales was partially offset by lower cost of sales and operating expenses, achieved on the back of the company’s cost-reduction initiatives.
For 2016, Ingevity Corporation anticipates benefiting from the strength in its Performance Materials segment. Also, the company anticipates higher demand for innovative pavement chemistries in its Performance Chemicals segment. On the back of these positives, the company has raised its sales guidance to $880−$910 million, with a mid-point of $895 million, from the previous outlook of $870−$910 million, with a mid-point of $890 million. Also, the company’s cost-reduction efforts are estimates to result in $25−$30 million savings in the year.
We believe that the impressive outlook created positive momentum for Ingevity Corporation, driving the company’s share price higher by 21.8% since the release of second-quarter 2016 results on Aug 3.
Estimate Revisions Show Potency
Over the last 60 days, the Zacks Consensus Estimate for Ingevity Corporation grew 6.1% to $1.92 for 2016 and 2.6% to $2.36 for 2017. The estimate for 2017 represents year-over-year growth of 22.9%.
With a market capitalization of approximately $2 billion, Ingevity Corporation carries a Zacks Rank #2 (Buy). Other stocks worth considering in the chemical-diversified industry include NL Industries Inc. (NL - Free Report) , Green Plains Inc. (GPRE - Free Report) and Minerals Technologies Inc. (MTX - Free Report) . While NL Industries sports a Zacks Rank #1(Strong Buy), both Green Plains and Minerals Technologies carry the same Zacks Rank as Ingevity Corporation. You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What Drove Ingevity Corporation to a New 52-week High?
Shares of Ingevity Corporation (NGVT - Free Report) reached a new 52-week high of $46.71 on Sep 15, before closing the trading session slightly lower at $46.21. This apex improved upon the last 52-week high of $46.57 on Sep 6.
The trading volume for the session on Sep 15 was 0.56 million shares. Earnings estimate revisions for 2016 and 2017 as well as estimated earnings growth rate of 10% for the next 3−5 years indicate Ingevity Corporation’s potential for further price appreciation.
Growth Drivers
Financial performance of Ingevity Corporation in the last quarter was impressive, with earnings of 66 cents per share surpassing the Zacks Consensus Estimate of 49 cents by 34.7%. The decline of 5.1% in net sales was partially offset by lower cost of sales and operating expenses, achieved on the back of the company’s cost-reduction initiatives.
For 2016, Ingevity Corporation anticipates benefiting from the strength in its Performance Materials segment. Also, the company anticipates higher demand for innovative pavement chemistries in its Performance Chemicals segment. On the back of these positives, the company has raised its sales guidance to $880−$910 million, with a mid-point of $895 million, from the previous outlook of $870−$910 million, with a mid-point of $890 million. Also, the company’s cost-reduction efforts are estimates to result in $25−$30 million savings in the year.
We believe that the impressive outlook created positive momentum for Ingevity Corporation, driving the company’s share price higher by 21.8% since the release of second-quarter 2016 results on Aug 3.
Estimate Revisions Show Potency
Over the last 60 days, the Zacks Consensus Estimate for Ingevity Corporation grew 6.1% to $1.92 for 2016 and 2.6% to $2.36 for 2017. The estimate for 2017 represents year-over-year growth of 22.9%.
INGEVITY CORP Price and Consensus
INGEVITY CORP Price and Consensus | INGEVITY CORP Quote
With a market capitalization of approximately $2 billion, Ingevity Corporation carries a Zacks Rank #2 (Buy). Other stocks worth considering in the chemical-diversified industry include NL Industries Inc. (NL - Free Report) , Green Plains Inc. (GPRE - Free Report) and Minerals Technologies Inc. (MTX - Free Report) . While NL Industries sports a Zacks Rank #1(Strong Buy), both Green Plains and Minerals Technologies carry the same Zacks Rank as Ingevity Corporation. You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>